Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

Battipaglia, Giorgia; Ruggeri, Annalisa; Massoud, Radwan; Cheikh, Jean El; Jestin, Matthieu; Antar, Ahmad; Ahmed, Syed Osman; Rasheed, Walid; Shaheen, Marwan; Belhocine, Ramdane; Brissot, Éolia; Duléry, Rémy; Eder, Sandra; Giannotti, Federica; Isnard, F; Lapusan, Simona; Rubio, Marie‐Thérèse; Vekhoff, Anne; Aljurf, Mahmoud; Legrand, Ollivier; Mohty, Mohamad; Bazarbachi, Ali

doi:10.1002/cncr.30680

Cited by 104 publications

(69 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing body of clinical evidence indicates that whether sorafenib is used before or after transplantation, sorafenib in combination with allo-HSCT might benefit patients with FLT3-ITD AML. [10][11][12][13][14] However, these studies had small samples, and to our knowledge, there is a lack of comparative studies on the efficacy of sorafenib therapy before and after transplantation. In this large-sample, retrospective study, we compared the effects of sorafenib at different time points on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT.…”

Section: Discussionmentioning

confidence: 99%

“…8 A growing body of clinical studies suggests that chemotherapy combined with sorafenib might promote longer remissions for patients with FLT3-ITD AML, especially for patients younger than 60 years. [12][13][14] In this study, we retrospectively evaluated the effect of sorafenib therapy on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT. [12][13][14] In this study, we retrospectively evaluated the effect of sorafenib therapy on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT.…”

Section: Introductionmentioning

confidence: 99%

“…[9][10][11] Sorafenib maintenance after allo-HSCT has been proved to be safe for patients with FLT3-ITD AML, but whether it could improve survival remains uncertain. [12][13][14] In this study, we retrospectively evaluated the effect of sorafenib therapy on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of sorafenib on the outcomes of patients with FLT3‐ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Xuan

Wang

Huang

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of sorafenib on the outcomes of patients with FLT3‐ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Xuan

Wang

Huang

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the RI post ASCT, including late relapses, has been shown to be higher than following allo‐HSCT, due to the absence of a graft‐vs‐leukemia effect . In patients allotransplanted, several attempts at reducing the RI post‐transplant have given interesting results, using tyrosine kinase inhibitors such as sorafenib, midostaurin, or PD1/PD1L inhibitors. No such approach has been tested so far in the context of ASCT although the rationale would be solid.…”

Section: Discussionmentioning

confidence: 99%

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT

et al. 2018

Self Cite

View full text Add to dashboard Cite

Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38.8], and nonrelapse mortality (NRM) 33.7% [95%CI 29.6-37.9]. RI was higher in patients transplanted in relapse in comparison to those transplanted in CR2 (HR 1.76, P = .004) and in patients who relapsed later after ASCT (HR 0.97 per month, P < 10 ), both translating into better LFS/ OS. Relapse was also lower in patients undergoing allogeneic stem cell transplantation (allo-HSCT) from an unrelated donor (UD) in comparison to those transplanted from a matched sibling donor (MSD) (HR 0.49, P < 10 ). NRM was increased in patients who received total body irradiation (TBI) pre-ASCT (HR 2.43; P < 10-4), translating into worse LFS/OS. LFS/OS did not differ between patients allotransplanted with reduced intensity (RIC) or myeloablative (MAC) conditioning. In conclusion, one third of adult patients with AML relapsing post ASCT can be rescued with allo-HSCT, with better LFS/OS in patients who relapsed later post ASCT, those transplanted in CR2 and those who had not received TBI pre-ASCT.

show abstract

“…The rates of NRM or cGVHD were no different between groups. Meanwhile, other retrospective studies have also reported encouraging outcomes with the use of sorafenib as post-alloHCT maintenance therapy [56,57].…”

Section: Gilteritinibmentioning

confidence: 99%

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Lee

Savani

Mohty

et al. 2018

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy generally associated with poor prognosis. Allogeneic hematopoietic cell transplantation (alloHCT) continues to be the most potent anti-leukemia treatment for adult patients with intermediate and high-risk AML. However, disease relapse after alloHCT remains unacceptably high and is the primary cause of treatment failure and mortality following alloHCT. It is therefore that post-transplant early cellular or pharmacologic maintenance or preemptive strategies to enhance the graft-versus-leukemia effect or to eradicate persistent minimal residual disease have been of renewed interest, particularly with the availability of more sensitive technologies to measure residual AML. Although preliminary studies have demonstrated improved outcomes with the use of post-alloHCT remission therapies, prospective randomized trials are required to determine their clinical efficacy and role in the treatment of AML. On behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use and efficacy of available pharmacologic post-remission therapies, including hypomethylating agents, deacetylase inhibitors, and tyrosine kinase inhibitors, as well as cellular therapies, including preemptive and prophylactic donor lymphocyte infusions for the prevention of relapse of AML.

show abstract

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

Cited by 104 publications

References 28 publications

Effect of sorafenib on the outcomes of patients with FLT3‐ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Effect of sorafenib on the outcomes of patients with FLT3‐ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Contact Info

Product

Resources

About